Amgen Inc. (AMGN) announced after the close Thursday that the U.S. District Court in Delaware granted the company’s request for a permanent injunction prohibiting Sanofi (SNY) and Regeneron Pharmaceuticals (REGN) from infringing two patents that Amgen holds for Repatha.
Amgen has gapped open sharply higher Friday morning and is now up 7.38 at $160.36. The stock has jumped to over a 2-month high and has re-crossed its 200-day moving average.
by RTT Staff Writer
For comments and feedback: [email protected]